Clinical Trials Browser

Leukemia, B-Cell

NCT06355739 2024-04-09

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

Phase NA Recruiting

60 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

NCT04090268 2024-01-02

SportTherapy

Phase NA Unknown

380 enrolled

LymphoidOther hematologic neoplasm

Adrenoleukodystrophy, Hodgkin Disease, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Motor Activity, Neoplasms, Sickle Cell Trait, Leukemia, B-Cell, Leukemia, T-Cell, Leukemia, Myeloid, Acute, beta-Thalassemia

NCT05350826 2023-09-21

THEMIS

Phase NA Unknown

450 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT05099068 2022-07-05

PLANET

Phase NA Unknown

500 enrolled

CNSLymphoidOther hematologic neoplasm

Glioblastoma, Leukemia, B-Cell

NCT03302403 2020-10-08

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Phase NA Unknown

18 enrolled

GastrointestinalLymphoidOther hematologic neoplasmPlasma cell

Carcinoma, Hepatocellular, Pancreatic Neoplasms, Leukemia, B-Cell, Lymphoma, B-Cell, Neoplasms, Plasma Cell

NCT03564977 2018-07-02

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Phase NA Unknown

20 enrolled

LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell, Neoplasm, Residual

NCT02813837 2016-06-28

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies

Phase NA Unknown

30 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence, Leukemia, B-Cell, Lymphoma, B-Cell

Clinical Trials

CLL-IMPACT

CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+

SportTherapy

THEMIS

PLANET

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies